U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H40O4P2
Molecular Weight 382.4553
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TETROFOSMIN

SMILES

CCOCCP(CCOCC)CCP(CCOCC)CCOCC

InChI

InChIKey=QCWJONLQSHEGEJ-UHFFFAOYSA-N
InChI=1S/C18H40O4P2/c1-5-19-9-13-23(14-10-20-6-2)17-18-24(15-11-21-7-3)16-12-22-8-4/h5-18H2,1-4H3

HIDE SMILES / InChI
Molecular Formula C18H40O4P2
Molecular Weight 382.4553
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Tetrofosmin is a phosphor-organic compound, belonging to the group of diphosphines. Tetrofosmin is used as a component of a Technetium (99mTc) tetrofosmin complex. Due to the relatively short half-life of Tc99m (6 hours), just before the administration, the solution of tetrofosmin should be reconstituted with Tc99m pertechnetate to form a complex of Tc99m Tetrofosmin. When administered intravenously, Tc99m Tetrofosmin shows rapid myocardial uptake and its distribution follows a linear relationship with coronary blood flow. It is taken up by the mitochondria of myocardial cells by passive diffusion and appears to accumulate in viable myocardial tissue. Tc99m Tetrofosmin is used as a diagnostic agent used to assess areas of reversible myocardial ischemia in the presence or absence of infracted myocardium and is also used to assess ventricular function.

Approval Year

1996
224
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Approved
8583
MYOVIEW

Approved Use

MYOVIEW is indicated for scintigraphic imaging of the myocardium following separate administrations under exercise and/or resting conditions. It is useful in the delineation of regions of reversible myocardial ischemia in the presence or absence of infarcted myocardium. MYOVIEW is also indicated for scintigraphic imaging of the myocardium to identify changes in perfusion induced by pharmacologic stress in patients with known or suspected coronary artery disease. MYOVIEW is also indicated for the assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients being evaluated for heart disease.

Launch Date

1996
PubMed

PubMed

TitleDatePubMed
[Study of pulmonary lesions with (99m)Tc-Tetrafosmin and chest spect. Determination of uptake related factors, diagnostic value and prognosis].
2002-04
Efficiency comparison between 99m Tc-tetrofosmin and 99m Tc-sestamibi myocardial perfusion studies.
2002-03
Detection of axillary lymph node metastases in breast cancer with Tc-99m tetrofosmin scintigraphy.
2002-03
Comparison of technetium-99m tetrofosmin and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
2002-02-19
Tetrofosmin imaging in the detection of myocardial viability in patients with previous myocardial infarction: comparison with sestamibi and Tl-201 scintigraphy.
2002-02-15
Using technetium-99m-tetrofosmin scan to predict chemotherapy response of malignant lymphomas, compared with P-glycoprotein and multidrug resistance related protein expression.
2002-02-12
Estimation of left ventricular systolic pressure by the left ventricular volume-time curve obtained from electrocardiograph gated 99m Tc-tetrofosmin single photon emission tomography using quantitative gated SPECT.
2002-02
201Tl, 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-furifosmin: relative retention and clearance kinetics in retrogradely perfused guinea pig hearts.
2002-02
[New trials for improving diagnostic accuracy of stress technetium-99m-tetrofosmin single photon emission computed tomography].
2002-01
Incremental prognostic value of myocardial SPET with dual-isotope rest (201)Tl/stress (99m)Tc-tetrofosmin.
2002-01
Intrathoracic and intra-abdominal Tl-201 abnormalities seen on rotating raw cine data on dual radionuclide myocardial perfusion and gated SPECT.
2002-01
Assessment of transient left ventricular dilatation on rest and exercise on Tc-99m tetrofosmin myocardial SPECT.
2002-01
Tc-99m MIBI, Tc-99m tetrofosmin, and Tc-99m (V) DMSA accumulation in recurrent malignant thymoma.
2002-01
Feasibility of myocardial dual-isotope perfusion imaging combined with gated single photon emission tomography for assessing coronary artery disease.
2002-01
Scintigraphic prediction of response to chemotherapy in patients with breast cancer: Technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography.
2002-01
Left ventricular function and infarct size 20 months after primary angioplasty for acute myocardial infarction.
2001-12
99mTc-Tetrofosmin pinhole-SPECT (P-SPECT) and radioguided sentinel node (SN) biopsy and in breast cancer axillary lymph node staging.
2001-12
Duodenogastric reflux on (99m)Tc-tetrofosmin myocardial SPECT mimics left ventricle inferior wall reverse redistribution and falsely decreases ejection fraction: a case report.
2001-12
Frequency and clinical significance of myocardial ischemia detected early after coronary stent implantation.
2001-12
Evaluation of left ventricular function using electrocardiographically gated myocardial SPECT with (123)I-labeled fatty acid analog.
2001-12
Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain.
2001-12
Technetium-99m tetrofosmin for parathyroid scintigraphy: a direct comparison with (99m)Tc-MIBI, (201)Tl, MRI and US.
2001-12
Early detection of myocardial ischaemia in the emergency department by rest or exercise (99m)Tc tracer myocardial SPET in patients with chest pain and non-diagnostic ECG.
2001-12
(99)mTc-tetrofosmin SPET in the detection of both primary breast cancer and axillary lymph node metastasis.
2001-12
Comparison between rest technetium-99m-tetrofosmin and rest-redistribution thallium-201 SPECT in stable patients with healed myocardial infarction.
2001-12
Assessment of adenosine, arbutamine and dobutamine as pharmacological stress agents during (99m)Tc-tetrofosmin SPECT imaging: a randomized study.
2001-12
[Stress-rest myocardial tomoscintigraphy with 99mTc-tetrofosmin in the diagnosis of ischemic disease].
2001-11-20
Early identification of impaired myocardial reperfusion with serial assessment of ST segments after percutaneous transluminal coronary angioplasty during acute myocardial infarction.
2001-11-01
[Examination concerning dissociation of left ventricular volume calculation value based on difference of analytical algorithm and perfusion tracer in gated myocardial SPECT].
2001-11
[Improvement of 99mTc-pyrophosphate scintigraphy in detection of acute myocardial infarction: combined with 99mTc-tetrofosmin].
2001-11
Giant mediastinal parathyroid adenoma in a woman with hypercalcemia.
2001-11
Estimation of coronary flow reserve with the use of dynamic planar and SPECT images of Tc-99m tetrofosmin.
2001-10-11
Exercise-induced myocardial perfusion abnormalities in sickle beta-thalassemia: Tc-99m tetrofosmin gated SPECT imaging study.
2001-10-01
[An approach for comparative quantification of myocardial blood flow (O-15-H2O-PET), perfusion (Tc-99m-tetrofosmin-SPECT) and metabolism (F-18-FDG-PET)].
2001-10
[Prognostic value of myocardial perfusion SPECT in multivessel coronary disease patients with left ventricular dysfunction, comparing revascularized and non-revascularized patients].
2001-10
Rapid quality control for testing the radiochemical purity of 99Tc(m)-tetrofosmin.
2001-10
Predicting chemotherapy response and comparing with P-glycoprotein expression using technetium-99m tetrofosmin scan in untreated malignant lymphomas.
2001-09-20
New trends in parathyroid scintigraphy.
2001-09
[Usefulness of combination post-stress dysfunction and perfusion imaging in technetium-99m-tetrofosmin myocardial scintigraphy].
2001-09
Time course evaluation of myocardial perfusion after reperfusion therapy by 99mTc-tetrofosmin SPECT in patients with acute myocardial infarction.
2001-09
Quantification of limited augmentation of myocardial (99m)Tc-tetrofosmin uptake at exercise in stable coronary artery disease.
2001-09
Assessment of ampulla (Takotsubo) cardiomyopathy with coronary angiography, two-dimensional echocardiography and 99mTc-tetrofosmin myocardial single photon emission computed tomography.
2001-08
Dynamic changes in cardiac fatty acid metabolism in the stunned human myocardium.
2001-08
Study of tea polyphenol as a reversal agent for carcinoma cell lines' multidrug resistance (study of TP as a MDR reversal agent).
2001-08
Detection of malignant thymoma in primary tumor and metastatic lesions using 99mTc-tetrofosmin scintigraphy.
2001-07-27
Comparing 18-fluoro-2-deoxyglucose positron emission tomography with a combination of technetium 99m tetrofosmin single photon emission computed tomography and computed tomography to detect recurrent or persistent nasopharyngeal carcinomas after radiotherapy.
2001-07-15
99Tc(m)-tetrofosmin scintimammography for detecting breast cancer: a comparative study with 99Tc(m)-MIBI.
2001-07
99mTc-tetrofosmin for functional imaging of P-glycoprotein modulation in vivo.
2001-07
Perfusion and functional abnormalities outside the septal region in patients with left bundle branch block assessed with gated SPECT.
2001-03
Recurrent hyperparathyroidism after total parathyroidectomy due to multiple ectopic parathyroid glands in a patient with long-term haemodialysis.
2001
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:59:19 GMT 2025
Edited
by admin
on Mon Mar 31 17:59:19 GMT 2025
Record UNII
3J0KPB596Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
P-53
Preferred Name English
TETROFOSMIN
II   INN   JAN   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
TETROFOSMIN [USAN]
Common Name English
TETROFOSMIN [JAN]
Common Name English
tetrofosmin [INN]
Common Name English
Tetrofosmin [WHO-DD]
Common Name English
3,12-DIOXA-6,9-DIPHOSPHATETRADECANE, 6,9-BIS(2-ETHOXYETHYL)-
Systematic Name English
Ethylenebis[bis(2-ethoxyethyl)phosphine]
Systematic Name English
TETROFOSMIN [II]
Common Name English
TETROFOSMIN [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1937
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
EU-Orphan Drug EU/3/16/1764
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C66594
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY
USAN
EE-5
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY
INN
6886
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY
FDA UNII
3J0KPB596Q
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY
SMS_ID
100000082740
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY
DRUG CENTRAL
3592
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY
RXCUI
1311569
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY RxNorm
EVMPD
SUB10950MIG
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY
DRUG BANK
DB11180
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY
CAS
127502-06-1
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY
MERCK INDEX
m10665
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY Merck Index
DAILYMED
3J0KPB596Q
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY
EPA CompTox
DTXSID70155591
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY
ChEMBL
CHEMBL1615784
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY
PUBCHEM
4274
Created by admin on Mon Mar 31 17:59:19 GMT 2025 , Edited by admin on Mon Mar 31 17:59:19 GMT 2025
PRIMARY
Related Record Type Details
Structure of 2,2-BIS(HYDROXYMETHYL)-1-AZABICYCLO(2,2,2,)OCTAN-3-ONE
INHIBITOR -> TARGET
RITA
INHIBITOR -> TARGET
Structure of SERDEMETAN
INHIBITOR -> TARGET
ANTAGONIST
IC50
Structure of TECHNETIUM TC-99M TETROFOSMIN
LABELED -> NON-LABELED
Structure of NSC-319726
INHIBITOR -> TARGET
Structure of SAR-405838
INHIBITOR -> TARGET
MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1
ANTAGONIST
IC50
Structure of TENOVIN-1
INHIBITOR -> TARGET
Related Record Type Details
Structure of TETROFOSMIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966